Dr Andreas Jenne
Andreas is a serial entrepreneur with more than 20 years of leadership experience in the life sciences industry. He has founded six biotechnology companies to date. Among other appointments, Andreas has served as managing director of SciRhom, RSP Systems, Kinaxo Biotechnologies (sold to Evotec in 2011), and NEO New Oncology (sold to Siemens Healthcare in 2016). He is also an active board member of several biotechnology companies and CEO of Ventura BioMed Investors GmbH, a venture capital investor in early-stage biotechnology companies developing breakthrough technologies and innovative therapies. Andreas holds a PhD in chemistry from Ludwig-Maximilians-University in Munich.
Dr Thilo Schröder
Thilo is Managing Partner at Nextech Invest, a Zurich-based global venture capital firm focused on oncology therapeutics and driving value creation for its portfolio companies. As an expert in precision oncology medicines and best-in-class targeted therapies, he serves on the board of numerous companies, including Revolution Medicines, PMV Pharma, Circle Pharma, Atavistik Bio, MOMA Therapeutics, Silverback Therapeutics, Exo Therapeutics, and Alterome Therapeutics and was a prior board member at Blueprint Medicines and Peloton Therapeutics. Thilo began his career at the pioneering cancer immunology company Micromet (acquired by Amgen). He has a Master’s degree from the University of Strasbourg and a PhD from the University of Zurich.
